Skip to main content
PolyPeptide Group AG logo

PolyPeptide Group AG — Investor Relations & Filings

Ticker · PPGN ISIN · CH1110760852 LEI · 5067007JCKTPOX4G9758 SW Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2021-08-17 Earnings Release
Country CH Switzerland
Listing SW PPGN

About PolyPeptide Group AG

https://www.polypeptide.com/

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Recent filings

Filing Released Lang Actions
PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad-hoc' announcement released on August 17, 2021, detailing 'results for the first half of 2021' (H1 2021). It provides key financial figures, management commentary, and an outlook, which are characteristic of an Earnings Release (ER). However, it also mentions the release of the 'half-year report 2021' and provides links to the results presentation and the full report. Since the document itself contains the detailed financial highlights, management discussion, and guidance update, it functions as the primary announcement of the period results. Given the comprehensive nature of the financial data presented (tables, growth rates, margin analysis) and the context of reporting on a period shorter than a year (H1), the most appropriate classification is Interim / Quarterly Report (IR). While it shares characteristics with an Earnings Release (ER), the depth of detail suggests it is more than just the initial highlights release, aligning better with the comprehensive nature of an IR. H1 2021
2021-08-17 English
PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
Board/Management Information Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" release and states it is a "Release of an ad hoc announcement pursuant to Art. 53 LR". The content details the appointment of a new General Counsel and Executive Committee member. This type of announcement, concerning significant internal management changes, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-06-25 English
PolyPeptide Group announces the exercise of the full over-allotment option
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' announcement dated May 5, 2021, detailing the exercise of the full over-allotment option following an Initial Public Offering (IPO) on the SIX Swiss Stock Exchange. This announcement concerns a significant capital market transaction (the finalization of the share offering post-IPO) and the resulting capital structure change (free float percentage). This fits best under the 'Capital/Financing Update' category, as it directly relates to the completion of a fundraising/share issuance event. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure post-offering. Therefore, 'CAP' is the most appropriate classification.
2021-05-05 English
PolyPeptide Group prices IPO at CHF 64.00 per share and starts trading on the Swiss Stock Exchange
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the pricing of an Initial Public Offering (IPO) for PolyPeptide Group at CHF 64.00 per share and the start of trading on the Swiss Stock Exchange (SIX). Key terms like 'IPO', 'pricing', 'listing', 'new shares', 'offer price', and 'market capitalization' are central to the text. This activity relates directly to raising capital and changing the company's structure via public offering, which aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about a major financing event.
2021-04-29 English
PolyPeptide Group launches IPO on the Swiss Stock Exchange and sets price range at CHF 57 to CHF 68 per share
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the 'launch of its initial public offering (IPO) on the Swiss Stock Exchange' and sets the 'price range'. It details the offering structure (new shares, existing shares, over-allotment option), the expected timeline (book-building dates, listing date), and the intended use of proceeds. This content is characteristic of a major financing or capital raising event, specifically an IPO announcement. This aligns directly with the definition for Capital/Financing Update (CAP). Although it mentions the offering memorandum, the primary focus is the announcement of the capital raising event itself, not just the publication of a report (RPA) or a general regulatory filing (RNS).
2021-04-21 English
PolyPeptide Group plans IPO and listing on the Swiss Stock Exchange
Capital/Financing Update Classification · 98% confidence The document is an official press release announcing the company's intention to launch an Initial Public Offering (IPO) and list its shares on the Swiss Stock Exchange (SIX). This type of announcement, detailing fundraising plans, capital structure changes, and the intention to issue new shares to the public, directly aligns with the definition of a Capital/Financing Update (CAP). Although it relates to shares, it is a financing event announcement rather than a routine transaction report (POS) or a general share change (SHA).
2021-04-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.